Potential Upside For Eiger's Avexitide In Both PBH And CHI Indications: Analyst
Portfolio Pulse from Vandana Singh
Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) announced it will focus on advancing avexitide in hyperinsulinemic hypoglycemia indications. The company will allocate resources towards the potential of avexitide in treating metabolic diseases, primarily post-bariatric hypoglycemia (PBH). Baird raised the price target for EIGR from $3 to $5 with an Outperform rating, citing a shift away from virology. The analyst sees upside potential in both PBH and congenital hyperinsulinism (CHI) indications. EIGR shares are up 16.36% at $0.6401.
June 30, 2023 | 6:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eiger BioPharmaceuticals is shifting its focus to avexitide in hyperinsulinemic hypoglycemia indications. Baird raised the price target for EIGR from $3 to $5, indicating a positive outlook for the company. EIGR shares are up 16.36%.
The company's decision to focus on avexitide in hyperinsulinemic hypoglycemia indications is seen as a positive move by Baird, leading to a price target increase. This news, along with the company's stock price increase, indicates a positive short-term impact on EIGR's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100